Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation

Cyclin-dependent kinase 2 (CDK2) has been garnering considerable interest as a target to develop new cancer treatments and to ameliorate resistance to CDK4/6 inhibitors. However, a selective CDK2 inhibitor has yet to be clinically approved. With the desire to discover novel, potent, and selective CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanta, Biruk Sintayehu, Lenjisa, Jimma, Teo, Theodosia, Kou, Lianmeng, Mekonnen, Laychiluh, Yang, Yuchao, Basnet, Sunita K. C., Hassankhani, Ramin, Sykes, Matthew J., Yu, Mingfeng, Wang, Shudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096391/
https://www.ncbi.nlm.nih.gov/pubmed/37049714
http://dx.doi.org/10.3390/molecules28072951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096391/
https://www.ncbi.nlm.nih.gov/pubmed/37049714
http://dx.doi.org/10.3390/molecules28072951

Ejemplares similares